MMIT Reality Check on HeFH (Mar 2021)

According to our recent payer coverage analysis for HeFH treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for HeFH treatments shows that under the pharmacy benefit, about 66% of the lives under commercial formularies are covered with utilization management
restrictions.

Trends: In February 2020, the FDA approved Esperion Therapeutics, Inc.’s Nexletol (bempedoic acid) tablet, a once-daily, non-statin LDL-cholesterol-lowering medicine, for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

red-blood-cells-carry-oxygen-to-all-body-tissues-blood-transfusion-and-donation
September 30

MMIT Reality Check on Sickle Cell Disease (September 2022)

Read More
professional-psychologist-doctor-consult-in-psychotherapy-session
September 23

MMIT Reality Check on Schizophrenia (September 2022)

Read More
woman-suffering-from-bad-headache-or-migraine-appointment-with-doctor-in-office-room
September 16

MMIT Reality Check on Acute Migraine (September 2022)

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today